Johnson & Johnson (NYSE:JNJ) Stock Price Up 0.3% – Here’s What Happened

by · The Cerbat Gem

Shares of Johnson & Johnson (NYSE:JNJ – Get Free Report) rose 0.3% during mid-day trading on Monday . The company traded as high as $157.58 and last traded at $155.92. Approximately 1,432,065 shares traded hands during mid-day trading, a decline of 79% from the average daily volume of 6,966,644 shares. The stock had previously closed at $155.47.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of recent research reports. TD Securities cut their price objective on shares of Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Daiwa Capital Markets downgraded shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Morgan Stanley raised their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Finally, Sanford C. Bernstein raised their price objective on shares of Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. Seven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $175.00.

Read Our Latest Report on Johnson & Johnson

Johnson & Johnson Stock Performance

The stock’s 50-day moving average is $162.61 and its 200-day moving average is $155.91. The stock has a market cap of $374.17 billion, a price-to-earnings ratio of 22.56, a P/E/G ratio of 2.76 and a beta of 0.53. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. During the same period last year, the business posted $2.66 earnings per share. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. On average, analysts expect that Johnson & Johnson will post 9.93 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a yield of 3.19%. Johnson & Johnson’s payout ratio is presently 71.78%.

Insider Buying and Selling

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.16% of the company’s stock.

Institutional Trading of Johnson & Johnson

Institutional investors and hedge funds have recently modified their holdings of the company. LPL Financial LLC boosted its stake in Johnson & Johnson by 10.2% in the 3rd quarter. LPL Financial LLC now owns 3,714,260 shares of the company’s stock valued at $601,933,000 after buying an additional 344,641 shares in the last quarter. German American Bancorp Inc. raised its holdings in shares of Johnson & Johnson by 7.7% in the third quarter. German American Bancorp Inc. now owns 50,275 shares of the company’s stock valued at $8,148,000 after buying an additional 3,612 shares during the last quarter. America First Investment Advisors LLC raised its holdings in shares of Johnson & Johnson by 2.0% in the third quarter. America First Investment Advisors LLC now owns 126,437 shares of the company’s stock valued at $20,490,000 after buying an additional 2,441 shares during the last quarter. Landscape Capital Management L.L.C. bought a new position in shares of Johnson & Johnson in the third quarter valued at about $365,000. Finally, Overbrook Management Corp grew its position in shares of Johnson & Johnson by 3.4% during the 3rd quarter. Overbrook Management Corp now owns 6,455 shares of the company’s stock worth $1,046,000 after buying an additional 212 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Company Profile

(Get Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Further Reading